TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8799769

Group type: EXPERIMENTAL
Intervention: Antisaccades with unpredictable target location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-target saccades with unpredictable target location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades with both target position and type of saccade unpredictable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-target saccades with both target position and type of saccade unpredictable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades with predictable target location and unpredictable type of saccade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-target saccades with predictable target location and unpredictable type of saccade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades with both target position and type of saccade predictable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-target saccades with both target position and type of saccade predictable
Number of subjects: 0
Study: 1452797

Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrices with diatomaceous earth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrices with silica-based abrasive system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 4092799

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) taken with breakfast; four types of breakfast differing by lipid content.
Number of subjects: 103
Study: 31301609

Group type: EXPERIMENTAL
Intervention: Daily patient-reported anxiety measured using smartphones
Number of subjects: 84
Study: 28840585

Group type: EXPERIMENTAL
Intervention: Quxie Capsule combined with conventional therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo combined with conventional therapy
Number of subjects: 60
Study: 26979583

Group type: EXPERIMENTAL
Intervention: PRO-2 (2 Large High-Protein meals)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PRO-6 (6 Small High-Protein meals)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON-2 (2 Large Low-Protein meals)
Number of subjects: 10
Study: 25556888

Group type: EXPERIMENTAL
Intervention: Neuromuscular training program (eccentric hamstring muscle strength, plyometrics, and free/resisted sprinting exercises)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular football training (Control Group)
Number of subjects: 60
Study: 23546864

Group type: EXPERIMENTAL
Intervention: Double crown of spiral tackers (DC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sutures and tackers (S&T)
Number of subjects: 76
Study: 19959609

Group type: EXPERIMENTAL
Intervention: Goshgarian palatal arch
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nance palatal arch
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both Goshgarian and Nance palatal arches
Number of subjects: 57
Study: 18798438

Group type: EXPERIMENTAL
Intervention: Cervex-brush
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Cervex-mex
Number of subjects: 1658
Study: 16829344

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (PUFA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High saturated fat diet (SAFA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: High PUFA diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: High SAFA diet
Number of subjects: 70
Study: 14638346

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam and Meperidine
Number of subjects: 20
Study: 10971543

Group type: EXPERIMENTAL
Intervention: Digital X-ray radiogrammetry (DXR) method
Number of subjects: 40
Study: 8844447

Group type: EXPERIMENTAL
Intervention: BAY x 1005 (250 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: theophylline (400 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: BAY x 1005 and theophylline concomitantly (treatment C)
Number of subjects: 12
Study: 1621751

Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg, twice daily)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Cefaclor (250 mg, three times daily)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 393

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 393
Study: 6463091

Group type: EXPERIMENTAL
Intervention: d-amphetamine (5-30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30368666

Group type: EXPERIMENTAL
Intervention: EBC–DNA analysis for KRAS mutation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cancer tissue analysis for KRAS mutation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Detection of KRAS mutations at codon 12
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal lung tissue analysis
Number of subjects: 51
Study: 28741741

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pregabalin after low dose of morphine
Number of subjects: 34
Study: 26803590

Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 2381

Group type: EXPERIMENTAL
Intervention: Vitamin B6 and folic acid/B12 treatment
Number of subjects: 2381

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2381

Group type: COMPARATOR
Intervention: Folic acid/B12 treatment
Number of subjects: 2381
Study: 23369770

Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Handheld nebulizer (HHN)
Number of subjects: 54
Study: 23377603

Group type: EXPERIMENTAL
Intervention: Face-to-face self-management educational program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 20035492

Group type: EXPERIMENTAL
Intervention: Weight loss group (5% body weight reduction)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no weight reduction)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weight loss group
Number of subjects: 14
Study: 18753861

Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg once daily for 24 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Entecavir for 48 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Entecavir and Placebo (both groups)
Number of subjects: 68
Study: 15923264

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 32
Study: 12540412

Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg at -90 and 0 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10553750

Group type: EXPERIMENTAL
Intervention: Community reintegration skills training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 32
Study: 8510517

Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) therapy for 12 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 16
Study: 2881420

Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Clonidine (3 micrograms/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Guanfacine (15 micrograms/kg)
Number of subjects: 5
Study: 31342226

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CCFM8610
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum CCFM16
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: COMPARATOR
Intervention: Oligosaccharides
Number of subjects: 109
Study: 28801034

Group type: EXPERIMENTAL
Intervention: Electric stimulation plus standard pelvic floor muscle training
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard pelvic floor muscle training alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Electric stimulation plus standard pelvic floor muscle training and Standard pelvic floor muscle training alone
Number of subjects: 114
Study: 27223641

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg orally, twice daily preoperatively, and 0.5 mg, twice daily until hospital discharge)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no colchicine)
Number of subjects: 140
Study: 25862614

Group type: EXPERIMENTAL
Intervention: 2-meal frequency (2 MF)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 6-meal frequency (6 MF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both 2 MF and 6 MF
Number of subjects: 11
Study: 24519692

Group type: EXPERIMENTAL
Intervention: Risperidone 2.5 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21788602

Group type: EXPERIMENTAL
Intervention: Simultaneous lowering of systolic blood pressure and LDL cholesterol
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Achieved systolic blood pressure
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Achieved LDL cholesterol
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Lower achieved levels of systolic blood pressure
Number of subjects: 413
Study: 19464465

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 94

Group type: COMPARATOR
Intervention: Atrioventricular universal pacing
Number of subjects: 94

Group type: COMPARATOR
Intervention: Atrial inhibited pacing
Number of subjects: 94
Study: 16455420

Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography (TTDE) measuring coronary flow velocity reserve (CFVR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Tl‐201 single‐photon emission computed tomography (SPECT)
Number of subjects: 107
Study: 15767982

Group type: EXPERIMENTAL
Intervention: Ankle peak systolic velocity (APSV)
Number of subjects: 63
Study: 11737108

Group type: EXPERIMENTAL
Intervention: Onlay graft associated with a non-resorbable membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Onlay graft alone
Number of subjects: 0
Study: 10461448

Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg or 9 mg/kgbw/day (Group B)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Parenteral therapy (Group A)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Ceftibuten (Group B)
Number of subjects: 131
Study: 8150836

Group type: EXPERIMENTAL
Intervention: Collagenase ointment and polymyxin B sulfate/bacitracin spray
Number of subjects: 15

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 15
Study: 2681858

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 13
Study: 4343464

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with diazepam alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with diazepam and atropine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with chlormethiazole
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Post-procedure risk
Number of subjects: 65
Study: 31267576

Group type: COMPARATOR
Intervention: Group 1 (Control): Answered a control question about prior night's sleep
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Group 2: Answered sleep question and a question about fear of having blood drawn
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Group 3: Answered sleep question, fear of having blood drawn question, and four questions about specific donation-related fears (seeing blood, needles, pain, fainting)
Number of subjects: 2716
Study: 28627290

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (ACB) with 0.2% ropivacaine, 20 mL bolus followed by continuous flow at 6 mL/h for 2 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Single-dose local infiltration anesthesia (LIA) alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 69
Study: 25441094

Group type: EXPERIMENTAL
Intervention: Cpr + DF
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tms + DF
Number of subjects: 79

Group type: COMPARATOR
Intervention: AHT alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study: 24350813

Group type: EXPERIMENTAL
Intervention: Risperidone (maximum weight-based dose of 1.25 mg/day for 20 to <45 kg, and 1.75 mg/day for ≥ 45 kg)
Number of subjects: 79
Study: 21679325

Group type: EXPERIMENTAL
Intervention: Alpine skiing for 12 weeks (28.5 ± 2.6 skiing days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no skiing training)
Number of subjects: 22
Study: 18409002

Group type: EXPERIMENTAL
Intervention: pegylated interferon +/− lamivudine for 52 months
Number of subjects: 18
Study: 15876429

Group type: EXPERIMENTAL
Intervention: Non-symbolic arithmetic tasks
Number of subjects: 0
Study: 13680248

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 10718508

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise training (HI, 80% Vo2max, n = 10)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training (MOD, 40% Vo2max, n = 8)
Number of subjects: 18
Study: 9535623

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 293
Study: 8357109

Group type: EXPERIMENTAL
Intervention: Home oximetry testing
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Negative home oximetry test result
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Positive home oximetry test result
Number of subjects: 240
Study: 2875059

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 29544449

Group type: EXPERIMENTAL
Intervention: Diagnostic model including clinical and laboratory parameters
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Diagnostic model aiming for complete identification of sepsis cases
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Proposed model
Number of subjects: 296
Study: 26676082

Group type: EXPERIMENTAL
Intervention: Augmentation procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonaugmentation procedure
Number of subjects: 40
Study: 24911814

Group type: EXPERIMENTAL
Intervention: Pain Group (topical capsaicin cream)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pain Group
Number of subjects: 29
Study: 23213981

Group type: EXPERIMENTAL
Intervention: Warming-promoting needling technique
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 188

Group type: COMPARATOR
Intervention: Medication (salvia injectio and mecobalamin)
Number of subjects: 188
Study: 20555377

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study: 18569691

Group type: EXPERIMENTAL
Intervention: Recall of true negative events (M=3.31/5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recall of true positive events (M=2.61/5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False events recalled (M=2.15 false events recalled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False negative events recalled
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False positive events recalled
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detail of memories for negative events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detail of false negative event memories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissociation scores
Number of subjects: 0
Study: 16415626

Group type: EXPERIMENTAL
Intervention: Infant massage (tactile and kinesthetic stimulation), administered twice daily for 10 days.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no massage intervention).
Number of subjects: 26
Study: 12444335

Group type: EXPERIMENTAL
Intervention: 0.12% betamethasone‐17‐valerate ointment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control petrolatum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 8
Study: 10599897

Group type: EXPERIMENTAL
Intervention: Individualized multidisciplinary, outpatient 12‐month rehabilitation programme
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 50
Study: 8735556

Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide vaccine
Number of subjects: 0
Study: 1930060

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7022707

Group type: EXPERIMENTAL
Intervention: Mesentericocaval shunt
Number of subjects: 49

Group type: COMPARATOR
Intervention: Portacaval anastomosis
Number of subjects: 49
Study: 30527907

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS at 10 Hz over the ipsilesional primary motor cortex (M1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) rTMS at 1 Hz over the contralesional M1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 28106767

Group type: EXPERIMENTAL
Intervention: e-CA (electronic mobile-based food record)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-CA
Number of subjects: 0

Group type: COMPARATOR
Intervention: paper-based food record
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-hour telephone recalls
Number of subjects: 0
Study: 25920299

Group type: EXPERIMENTAL
Intervention: Lifestyle Change plus Dental Care (LCDC) program
Number of subjects: 132

Group type: COMPARATOR
Intervention: Routine program (Control)
Number of subjects: 132
Study: 23327503

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Integrated Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 0
Study: 21409705

Group type: EXPERIMENTAL
Intervention: Adolescents' reports about their parents' parenting behaviors
Number of subjects: 252

Group type: COMPARATOR
Intervention: Parent reports of parenting practices
Number of subjects: 252
Study: 19788461

Group type: EXPERIMENTAL
Intervention: Molecular adsorbents recirculating system (MARS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prometheus (FPAD)
Number of subjects: 8
Study: 17429636

Group type: EXPERIMENTAL
Intervention: LEF (100 mg/day for 3 days followed by 20 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX (25 mg once weekly)
Number of subjects: 40
Study: 15617455

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Enalapril 20 mg once daily
Number of subjects: 68
Study: 11348573

Group type: EXPERIMENTAL
Intervention: Coconut fat reduction (phase 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coconut fat reduction (phase 2, group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coconut fat reduction (phase 2, group B)
Number of subjects: 0
Study: 9561096

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 300
Study: 8489567

Group type: EXPERIMENTAL
Intervention: Immediate release formulation (300 mg, applied twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained release formulation (400 mg, applied once a day in the evening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate release formulation (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained release formulation (400 mg)
Number of subjects: 0
Study: 3583456

Group type: EXPERIMENTAL
Intervention: Oral nourishment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous nourishment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral and intravenous nourishment
Number of subjects: 14
Study: 31088753

Group type: EXPERIMENTAL
Intervention: Static stretching with 0s rest interval (R0)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static stretching with 30s rest interval (R30)
Number of subjects: 15
Study: 29957714

Group type: EXPERIMENTAL
Intervention: Intervention group (twice daily sessions of manual mobilization and 30‐minute passive/active cycling therapy)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (manual mobilization once a day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 27248838

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (aPDT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tongue scraper
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tongue scraper and photodynamic therapy
Number of subjects: 46
Study: 25171850

Group type: EXPERIMENTAL
Intervention: Repeated Exposure (RE) group; 0.2% salt w/w; n = 47
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Flavor-Flavor Learning with Salt (FFL-Salt) group; 0.5% salt w/w; n = 54
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Flavor-Flavor Learning with Nutmeg (FFL-Nutmeg) group; 0.2% salt and 0.02% nutmeg w/w; n = 50
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control vegetable (carrot puree)
Number of subjects: 151
Study: 23002547

Group type: EXPERIMENTAL
Intervention: Kurarinol combined with Diammonium Glycyrrhizinate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Kurarinol (single drug group)
Number of subjects: 63
Study: 19501011

Group type: EXPERIMENTAL
Intervention: Comprehension questionnaire administered at the end of the clinical trial
Number of subjects: 78
Study: 18396361

Group type: EXPERIMENTAL
Intervention: Na-ASP-2 vaccine (10 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Na-ASP-2 vaccine (50 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Na-ASP-2 vaccine (100 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study: 15647416

Group type: EXPERIMENTAL
Intervention: Anidulafungin 200 mg intravenous loading dose followed by 100 mg intravenous maintenance dose (days 2-8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.25 mg/kg oral solution twice daily (days 5-8)
Number of subjects: 12
Study: 12023065

Group type: EXPERIMENTAL
Intervention: Graded hand grip strength test (GST) at four intensities
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Perceived exertion (RPE-C) recorded at the end of each load level
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low grip force intensities
Number of subjects: 54